Display options
Cite
Masi L, Maddali Bongi S, Angotti C, et al. The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis. Clin Cases Miner Bone Metab. 2007;4(2):156-60
Masi, L., Maddali Bongi, S., Angotti, C., Del Monte, F., Carbonell Sala, S., Basetti, M., Amedei, A., Falchetti, A., & Brandi, M. L. (2007). The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 4(2), 156-60.
Masi, Laura, et al. "The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis." Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases vol. 4,2 (2007): 156-60.
Masi L, Maddali Bongi S, Angotti C, Del Monte F, Carbonell Sala S, Basetti M, Amedei A, Falchetti A, Brandi ML. The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis. Clin Cases Miner Bone Metab. 2007 May;4(2):156-60. PMID: 22461216; PMCID: PMC2781235.
Copy Download .nbib Format: NLM
Share it on

Clin Cases Miner Bone Metab. 2007 May;4(2):156-60.

The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis.

Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases

Laura Masi, Susanna Maddali Bongi, Chiara Angotti, Francesca Del Monte, Silvia Carbonell Sala, Massimo Basetti, Antonietta Amedei, Alberto Falchetti, Maria Luisa Brandi

Affiliations

  1. Department of Internal Medicine, University of Florence, Florence, Italy.

PMID: 22461216 PMCID: PMC2781235

Abstract

Objective. Osteoclast activation at the cartilage pannus junction is an essential step in the destruction of bone matrix in patients affected by rheumatoid arthritis (RA). Receptor activator of NFkappaB ligand (RANK-L) is responsible for osteoclast differentiation and activation. Osteoprotegerin (OPG) is an alternative, high-affinity soluble receptor for RANK-L which significantly inhibits osteoclastogenesis. Estrogens and the specific receptors α and β (ER-α and ER-α) are known to play an important role in the pathophysiology of osteoarthritis (OA). Scope of the present study is to investigate the role of ER-α and OPG gene polymorphisms in a group of women affected by RA.Materials and Methods. 139 consecutive RA patients (115 females and 34 males; median age 65.8 years) were selected. Bone mineral density (BMD) was measured by dual energy x-ray absorptinometry at the lumbar spine (LS-BMD) and femoral neck (FN-BMD) and the presence of bone erosions was evaluated by conventional X-ray. ER-α gene polymorphisms were determined by PvuII and XbaI restriction endonuclease digestion of polymerase chain reaction (PCR) products. By convention, the presence of the endonuclease restriction site was indicated with lowercase (p and x) letters while the absence of the restriction site was indicated with uppercase letters (P and X). OPG gene polymorphism was determined by RsaI restriction endonuclease digestion of PCR products and the presence and absence of restriction fragment was identified as TT and CC respectively.Results. Pearson's χ(2)analysis for the ER-α gene polymorphism showed a prevalence of Pp genotype (58%) (p=0.04) and Xx (54%) (p=0.04) in the total population, without differences between males and females. We did not observed any significant differences between ER-α genotypes and LS-BMD. However subjects with xx or pp genotype had a lower LS-BMD in comparison with the opposite genotype.For OPG gene polymorphism, non significant differences in the distribution of the genotypes were observed between males and females. In addition, we did not observed significant differences on LS-BMD between the genotypes.Finally, we observed that patients with ER-α pp genotype was significant more represented in patients with hand erosions (p = 0.05). No significant correlation was observed for ER-α XbaI genotype, however a trend characterized by a correlation between xx and hand erosions was observed (p = 0.13). For OPG gene polymorphism, we found a statistical correlation between C allele of OPG and hands bone erosions (p = 0.02).Conclusion. We found a significant association between ER-α and OPG gene polymorphisms and the presence of bone erosions in RA patients. These preliminary data suggest a role of ER-α and OPG gene polymorphisms in bone turnover and disease progression.

References

  1. Ann N Y Acad Sci. 2002 Jun;966:131-42 - PubMed
  2. Ann Rheum Dis. 1996 Nov;55(11):816-22 - PubMed
  3. J Rheumatol. 2004 May;31(5):986-91 - PubMed
  4. Arthritis Res. 2001;3(1):6-12 - PubMed
  5. J Rheumatol. 1998 Jan;25(1):134-7 - PubMed
  6. J Rheumatol. 1993 Aug;20(8):1288-96 - PubMed
  7. Cell. 1996 May 3;85(3):307-10 - PubMed
  8. N Engl J Med. 1990 May 3;322(18):1277-89 - PubMed
  9. Cancer Res. 1992 Jan 1;52(1):77-83 - PubMed
  10. JAMA. 2004 Nov 3;292(17):2105-14 - PubMed
  11. J Bone Miner Res. 2002 Jul;17(7):1245-55 - PubMed
  12. J Immunol. 1990 Jan 15;144(2):499-505 - PubMed
  13. Arthritis Rheum. 1991 Sep;34(9):1125-32 - PubMed
  14. J Bone Miner Res. 2000 Mar;15(3):392-401 - PubMed
  15. Arthritis Rheum. 2000 Apr;43(4):821-6 - PubMed
  16. Clin Exp Rheumatol. 1991 Nov-Dec;9(6):641-6 - PubMed
  17. J Endocrinol. 2000 Aug;166(2):235-45 - PubMed
  18. Genes Dev. 1998 May 1;12(9):1260-8 - PubMed
  19. Cell. 1997 Apr 18;89(2):309-19 - PubMed
  20. Arthritis Rheum. 1991 Nov;34(11):1444-51 - PubMed
  21. Arthritis Rheum. 1992 Oct;35(10):1197-201 - PubMed
  22. Arthritis Rheum. 1977 Jul-Aug;20(6):1231-9 - PubMed
  23. Cancer Res. 1989 Jan 1;49(1):145-8 - PubMed
  24. Br J Rheumatol. 1992 Dec;31(12):801-9 - PubMed
  25. Isr Med Assoc J. 2001 Oct;3(10):743-8 - PubMed
  26. Ann Rheum Dis. 1995 Nov;54(11):896-903 - PubMed
  27. J Bone Miner Res. 2000 Jul;15(7):1253-6 - PubMed
  28. Br J Rheumatol. 1993 Oct;32(10):903-7 - PubMed
  29. Cell. 1998 Apr 17;93(2):165-76 - PubMed
  30. Bone. 2001 Jan;28(1):104-7 - PubMed
  31. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602 - PubMed
  32. Arthritis Rheum. 1988 Mar;31(3):315-24 - PubMed
  33. Arthritis Rheum. 2000 Feb;43(2):250-8 - PubMed
  34. J Rheumatol. 1995 Mar;22(3):421-6 - PubMed
  35. Ann Rheum Dis. 2000 Sep;59(9):657-61 - PubMed
  36. J Bone Miner Res. 2006 Oct;21(10):1511-35 - PubMed
  37. Rheumatology (Oxford). 2001 Jun;40(6):623-30 - PubMed
  38. Hypertension. 1993 Apr;21(4):439-41 - PubMed
  39. Br J Rheumatol. 1992 Oct;31(10):653-61 - PubMed
  40. J Bone Miner Res. 1996 Mar;11(3):306-11 - PubMed
  41. Science. 1992 Jul 3;257(5066):88-91 - PubMed
  42. Arthritis Res Ther. 2005;7(4):R837-43 - PubMed
  43. Am J Epidemiol. 2005 Feb 15;161(4):307-20 - PubMed
  44. Arthritis Rheum. 2000 Feb;43(2):259-69 - PubMed
  45. J Clin Endocrinol Metab. 2002 Sep;87(9):4080-4 - PubMed
  46. J Steroid Biochem Mol Biol. 2002 May;81(1):1-24 - PubMed

Publication Types